Frazier Lifesciences Acquisition Corporation Stock
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.75 EUR | +1.24% | -0.37% | +67.86% |
Sales 2024 * | 8.61M 9.34M | Sales 2025 * | 6.3M 6.83M | Capitalization | 1.56B 1.69B |
---|---|---|---|---|---|
Net income 2024 * | -209M -227M | Net income 2025 * | -139M -151M | EV / Sales 2024 * | 181 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 247 x |
P/E ratio 2024 * |
-7.42
x | P/E ratio 2025 * |
-11.5
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
Latest transcript on Frazier Lifesciences Acquisition Corporation
1 day | +1.24% | ||
1 week | -0.37% | ||
1 month | -14.66% | ||
3 months | -20.35% | ||
6 months | +93.50% | ||
Current year | +67.86% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 18.75 | +1.24% | 547,724 |
24-05-30 | 18.52 | -2.42% | 92,903 |
24-05-29 | 18.98 | -2.22% | 103,242 |
24-05-28 | 19.41 | +3.13% | 236,777 |
24-05-24 | 18.82 | -1.47% | 131,706 |
End-of-day quote Nasdaq, May 30, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.86% | 1.69B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- NAMS Stock